There is currently no oral treatment for infections caused by extended-spectrum beta-lactamase-producing Enterobacterales. That single fact drives an enormous amount of unnecessary hospital admission and carbapenem use, and it is a daily problem in Indian practice, where ESBL rates in community urinary isolates are high enough that empirical oral options frequently fail.
This report pools three phase 1 trials in healthy participants evaluating avibactam tomilopil, an oral prodrug of avibactam, alone and combined with the oral cephalosporin ceftibuten. Avibactam tomilopil was rapidly converted to active avibactam, and plasma exposure rose proportionally with dose across 900 to 1350 mg. Avibactam and cis-ceftibuten had similar plasma half-lives and were both mainly renally excreted, which suits a urinary indication. Food had negligible effect on ceftibuten but raised avibactam exposure from the fixed-dose combination tablet.
Using joint probability of target attainment simulations from a population pharmacokinetic model, the investigators propose ceftibuten 400 mg with avibactam tomilopil 1200 mg every 8 hours, taken without regard to food, for phase 3 evaluation in complicated urinary tract infection.
This is dose selection, not efficacy. Nobody with an infection has been treated in these studies, and the entire case rests on modelled target attainment. It belongs in a briefing because of what it would mean if phase 3 succeeds: an oral agent that could keep ESBL urinary infections out of hospital and off carbapenems. That is the right level of interest — worth tracking, not worth anticipating.
- Nothing changes today: this is phase 1 dose selection, with efficacy still to be tested
- The proposed regimen for phase 3 is ceftibuten 400 mg plus avibactam tomilopil 1200 mg every 8 hours, food-independent
- Both components are renally cleared, so dose adjustment in impaired renal function will be a live question
- Meanwhile, the carbapenem-sparing options for ESBL urinary infection remain nitrofurantoin, fosfomycin and aminoglycosides where susceptibility allows
- Send urine cultures before starting empirical therapy so an oral step-down is possible when susceptibilities return
The statistics, in plain English
Joint probability of target attainment is a modelling technique, not a clinical result. It simulates thousands of virtual patients on a given dose and asks what proportion would achieve blood concentrations of both drugs high enough, for long enough, to kill a typical organism. It is a rational way to pick a dose to test, and it has been wrong before — target attainment predicts exposure, not cure, and says nothing about tolerability over a full treatment course or about emergent resistance. Treat the proposed regimen as a hypothesis entering phase 3.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free